GPC Biotech breast cancer drug enters phase II trial
4th Nov 2005, 03:24 GMT
A phase II trial has been initiated evaluating GPC Biotech's lead drug candidate, satraplatin, in patients with metastatic breast cancer who have received no more than one prior chemotherapy treatment regimen.
GPC Biotech breast cancer drug enters phase II trial related news:
- GPC Biotech: GPC Biotech Announces Start of Phase 2 Trial Evaluating Satraplatin in Patients With Metastatic Breast Cancer — Market Wire - Pharmaceuticals and Biotech
- GPC Biotech Announces Start of Phase 2 Trial Evaluating Satraplatin in Patients With Metastatic Breast Cancer — ArriveNet : Health
- Vaginal Atrophy Drug May Prevent Breast Cancer — The Cancer Blog
- Human Genome cancer drug proves safe in phase II trial — Pharmaceutical Business Review Online
- Amazon Biotech, Inc: Amazon Biotech Announces Preparation of IND for Early-Stage Breast Cancer Drug — Market Wire - Lifestyle and Leisure
- GPC Biotech startet Satraplatin-Phase-2-Studie gegen Brustkrebs — Finanztreff.de / NACHRICHTEN
- Breast Cancer Patients Testing Powerful Drug — NBC 17 - Health
- Colon-cancer drug success — RSS Top Stories -- SiliconValley.com
- Safer drug than tamoxifen found for fighting breast cancer — KeralaNext: Health
- GPC Biotech AG: GPC Biotech to Present at SG Cowen & Co. 6th Annual Global Health Care Conference in Barcelona — Market Wire - Pharmaceuticals and Biotech
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol